| rivaroxaban / Generic mfg. |
ChiCTR-TRC-14004379: To investigate the effects of different procoagulant drugs in combination anticoagulant for arthroplasty perioperative bleeding and the risk of thrombosis |
|
|
| Completed | 4 | 120 | | hemocoagulase + Rivaroxaban ;tranexamic acid + Rivaroxaban ;hemocoagulase + tranexamic acid + Rivaroxaban | Fujian Provincial Hospital; Level of the institution：, Fujian provincial hospital Fujian Emergency Center National key specialty construction of clinical project funding | artificial joint replacement | | | | |
2012-002263-96: dabigatran and rivaroxaban: prediction of anticoagulant effect Thrombin predict: Voorspellen van de mate van anticoagulante werking van twee orale anticoagulantia (dabigatran en rivaroxaban) |
|
|
| Ongoing | 4 | 60 | Europe | Film-coated tablet, Capsule, hard, xarelto rivaroxaban, Pradaxa dabigatran | MUMC, MUMC | non valvular atrial fibrillation atriumfibrilleren zonder kleplijden, atrial fibrillation without cardiac valve abnormalities atriumfibrilleren zonder klepafwijkingen, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2013-004484-31: Rivaroxaban and PCC: Prothrombin Complex Concentrate (Beriplex®) in patients with bleeding complications related to Rivaroxaban (Xarelto®) Rivaroxaban und PCC: Die Wirksamkeit von Prothrombin Komplex Kontentraten (Beriplex®) bei Patienten mit Blutungskomplikationen unter der Therapie mit Rivaroxaban (Xarelto®) |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Powder and solvent for solution for infusion, Xarelto, Beriplex | Medizinische Universität Innsbruck / Allg. u. chirug. Intensivmedizin, Medizinische Universität Innsbruck, CSL Behring | blood coagulation disorder Blutgerinnungsstörungen, treatment of bleeding Behandlung von Blutungen, Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR-TRC-14005223: Efficacy and Safety of rivaroxaban or warfarin on venous thromboembolic disease: A Randomized controlled trial |
|
|
| Recruiting | 4 | 40 | | Warfarin ;rivaroxaban | State Key Laboratory of Respiratory Disease, Guangzhou Institute of Respiratory Diseases, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China; First Affiliated Hospital of Guangzhou Medical Uni, self-financing | venous thromboembolic disease | | | | |
2013-000474-30: Investigation into the possibilities of finding antidotes for the new oral anti blood clotting agents Suche nach Medikamenten zur Umkehr der Wirkung der neuen oralen Antikoagulantien (NOACs) und neuen Blutplättchen-Hemmer (NOPAIs) |
|
|
| Ongoing | 4 | 120 | Europe | ELIQUIS, Pradaxa, Efient, Xarelto, Brilique, ELIQUIS, Pradaxa, Efient, Xarelto, Brilique | Medizinische Universität Innsbruck / Univ.-Klinik für Allg. u. Chirurg. Intensivmedizin, Medical University Innsbruck | blood coagulation disorders Blutgerinnungsstörungen | | | | |
ChiCTR-OPN-15005948: Pharmacokinetics of rivaroxaban in elderly patients with non-valvular atrial fibrillation |
|
|
| Recruiting | 4 | 16 | | rivaroxaban 15mg ;rivaroxaban 15mg | Zhejiang Hospital; Zhejiang Hospital, National Science and Technology Major Project of the Ministry of Science and Technology of China | non-valvular atrial fibrillation | | | | |
ChiCTR-OPN-15006584: Rivaroxaban versus warfarin during catheter ablation in patients with atrial fibrillation or atrial flutter |
|
|
| Recruiting | 4 | 200 | | rivaroxaban10mg or 15mg QD p.o. ;maintain INR 2-3 | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, autonomous | atrial fibrillation/atrial flutter | | | | |
ChiCTR-IPR-17012975: Effect of rivaroxaban on venous thromboembolism after posterior lumbar interbody fusion in elderly patients |
|
|
| Completed | 4 | 120 | | Rivaroxaban ;placebo | Guangzhou Panyu Hospital of Chinese Medicine; Guangzhou Panyu Hospital of Chinese Medicine, none | Venous thromboembolism | | | | |
2016-002105-18: Laboratory measurement of direct oral anticoagulants on patients with atrial fibrillation. |
|
|
| Ongoing | 4 | 200 | Europe | Pradaxa, Xarelto, Eliquis, Lixiana, Capsule, Coated tablet, Pradaxa, Xarelto, Eliquis, Lixiana | Helsinki City Hospital Haartman, Helsinki University Hospital | Non-valvular atrial fibrillation, Atrial fibrillation, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2016-002353-38: Optimal anticoagulation for patients with an increased risk for stroke after treatment of an heart arrhythmia (atrial fibrillation) by catheter ablation Optimale Gerinnungshemmung für Patienten mit einem erhöhten Risiko für Schlaganfall nach der Behandlung der Herzarrhythmie Vorhofflimmern durch Katheterablation |
|
|
| Not yet recruiting | 4 | 1572 | Europe | Xarelto, acetylsalicylic acid, Film-coated tablet, Tablet, Xarelto, acetylsalicylic acid of any trade name | Ottawa Heart Institute Research Corporation (OHIRC), Ottawa Heart Institute, Canadian Institute for Health Research, Biotronik Inc., Bayer Inc., Biotronik Inc. Canada | risk of stroke by atrial fibrillation durch Vorhofflimmern erhöhtes Schlaganfallrisiko, increased risk for stroke by atrial fibrillation, a heart arrhythmia durch Vorhofflimmern (eine Arrhythmie des Herzen) erhöhtes Risiko für Schlaganfall, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2017-000393-11: Blood thinners for frail elderly with a heart rhythm disorder |
|
|
| Ongoing | 4 | 2750 | Europe | Capsule, hard, Film-coated tablet, Tablet, Dabigatran ( Pradaxa), rivaroxaban (Xarelto), apixaban (Eliquis), edoxaban (Lixiana), acenocoumarol (Sintrom), fenprocumon (Marcoumar) | University Medical Center utrecht, ZonMw, Boehringer-Ingelheim, Bayer Healthcare, BMS Pfizer, Daiichi Sankyo | Atrial Fibrilation, heart rhythm disorder, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-PPR-15007044: A prospective, multi-center, randomized, pilot study of the watchman left atrial appendage occlusion device in patients with non-valvular atrial fibrillation versus rivaroxaban therapy |
|
|
| Not yet recruiting | 4 | 200 | | WATCHMAN LAA Occlusion Device ;Rivaroxaban | Guangdong Cardiovascular Institute, Guangdong General Hospital; Guangdong Cardiovascular Institute, Guangdong General Hospital, The research was supported by Science Technology Planning Project of Guangzhou, Boston Scientific Corporation Bayer Healthcare. | atrial fibrillation | | | | |
2017-003569-91: The effect of body weight on the medicine concentrations of dabigatran, edoxaban, apixaban and rivaroxaban in blood. |
|
|
| Ongoing | 4 | 160 | Europe | Apixaban, Dabigatran, Edoxaban, Rivaroxaban, EU/1/11/691/001, EU/1/08/442/001, EU/1/15/993/001, EU/1/08/472/025, Coated tablet, Capsule, hard, Eliquis, Pradaxa, Lixiane, Xarelto | Hagaziekenhuis, Hagaziekenhuis | No medical condition will be investigated. This study will only investigate the effect of body weight on through concentrations of direct oral anticoagulants (DOACs), No medical condition will be investigated. This study will only investigate the effect of body weight on the medicine concentrations of dabigatran, edoxaban, apixaban and rivaroxaban in blood., Not possible to specify | | | | |
ChiCTR-OPC-17011716: Analysis of the association among rivaroxaban blood concentration, anti-factor Xa activity and clinical prognosis in patients with deep vein thrombosis (DVT) treated with rivaroxaban |
|
|
| Recruiting | 4 | 70 | | rivaroxaban | Peking Union Medical College Hospital; Peking Union Medical College Hospital, self-raised fund | Deep vein thrombosis | | | | |
2018-001845-15: Evaluation of how well rivaroxaban is absorbed in patients with short bowel syndrom, based on laboratory markers and clinical outcomes such as thrombosis and bleeding. |
|
|
| Ongoing | 4 | 30 | Europe | Xarelto, Capsule, hard, Xarelto | Academic medical centre, department of internal medicine, Academic Medical centre, department of internal medicine | Chronic intestinal failuyre (IF) is caused by large surgical bowel resection, severe motility, or absorption diseorders. These patientds require partial or total parenteral nutrition (PN and TPN, respectively) and are thereby critically dependent on maintaining venous acces withj central venous catheter (CVC). CVC-related thrombosis is a frequent and serious complication that leads to catheter failure and is associated with CVC-infections and sepsis., Parenteral nutrition via central venous catheter is essential in patients unable to receive nutrition by oral intake or enteral tube feeding. Catheter-thrombosis is an important complication., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR-IPR-17011918: Safety and effectiveness of rivaroxaban in anticoagulation therapy for elderly patients |
|
|
| Recruiting | 4 | 200 | | rivaroxaban ;other anticoagulation therapy | Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Self-financing | thrombosis | | | | |
ChiCTR2000030143: Study for the antithrombotic therapy of rivaroxaban and clopidogrel after PCI in Chinese patients with acute coronary syndrome complicated with atrial fibrillation |
|
|
| Completed | 4 | 100 | | Rivaroxaban (15mg 1/ d) + clopidogrel (75mg 1/ d) | The second hospital of hebei medical university; the Second Hospital of Hebei Medical University, None | coronary heart disease | | | | |
2018-003299-11: Can additional treatment with a third blood thinning medication reduce the risk of further clots in heart arteries, in patients with a recent heart attack who are already taking two blood thinning medications. |
|
|
| Not yet recruiting | 4 | 150 | Europe | Rivaroxaban, Clopidogrel, Ticagrelor, Tablet, Film-coated tablet, Rivaroxaban, Clopidogrel, Ticagrelor | East and North Hertfordshire NHS Trust, Bayer PLC | Acute Coronary Syndrome, Heart attack, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2018-000753-45: Vitreorretinal surgery with and without oral anticoagulants: results and complications. CirugÃa vitreorretiniana con y sin anticoagulantes orales: resultados y complicaciones |
|
|
| Ongoing | 4 | 96 | Europe | Dabigatran, Apixaban, Rivaroxaban, Edoxaban, Acenocumarol, Enoxaparina, Capsule, hard, Coated tablet, Tablet, Solution for injection, PRADAXA, ELIQUIS, XARELTO, LIXIANA, SINTROM, CLEXANE | NAVARRBIOMED-FUNDACION MIGUEL SERVET, Navarrabiomed-Fundación Miguel Servet | Patients undergoing vitreoretinal surgery under treatment with oral anticoagulants Pacientes con indicación de cirugÃa vitreorretiniana y que estén en tratamiento con anticoagulantes orales, Patients undergoing vitreoretinal surgery under treatment with oral anticoagulants Pacientes con indicación de cirugÃa vitreorretiniana y que estén en tratamiento con anticoagulantes orales, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Surgical Procedures, Operative [E04] | | | | |
2018-001443-31: DOAC concentrations in blood prior to surgery study: DALI study |
|
|
| Not yet recruiting | 4 | 300 | Europe | Dabigatran, Rivaroxaban, Apixaban, EU/1/08/442/001, EU/1/08/472/025, EU/1/11/691/015, Capsule, hard, Coated tablet, Pradaxa, Xarelto, Eliquis | Leiden University Medical Center, Leiden University Medical Center | No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation., No medical condition will be investigated. This study will only investigate DOAC levels during surgery. Patients who use DOACs are patients with venous thrombosis and atrial fibrillation., Not possible to specify | | | | |
ChiCTR1800016829: anti-coagulation effect of aspirin, LMWH and rivaroxaban after total hip arthroplasty:a prospective randomised control trial |
|
|
| Recruiting | 4 | 240 | | aspirin ;LMWH ;rivaroxaban | Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University; Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University, self-fund | arthroplasty | | | | |
ChiCTR1800016830: Anti-coagulation effect of aspirin, LMWH and rivaroxaban after total knee arthroplasty without tourniquet: a prospective randomised control trial |
|
|
| Recruiting | 4 | 240 | | aspirin ;LMWH ;rivaroxaban | Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University; Department of Orthopaedic Surgery, West China Hospital, West China Medical School, Sichuan University, self-fund | arthroplasty | | | | |
ChiCTR-OPC-17012858: Safety and effectiveness of rivaroxaban in anticoagulation therapy for elderly patients with atrial fibrillation and venous thromboembolism: a prospective observational study |
|
|
| Recruiting | 4 | 200 | | rivaroxaban ;non-rivaroxaban | Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine; Xinhua Hospital Affiliated to Shanghai JiaoTong University School of Medicine, Self-financing | thrombosis | | | | |
| Completed | 4 | 72 | | Phase I:Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase II:Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase III:Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase IV:Rivaroxaban tablets manufactured by Bayer Pharma AG ;Phase I: Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase II: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase III: Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase IV: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD ;Phase I: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase II: Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase III: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase IV: Rivaroxaban tablets manufactured by Bayer Pharma AG ;Phase I: Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase II: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD; Phase III: Rivaroxaban tablets manufactured by Bayer Pharma AG; Phase IV: Rivaroxaban tablets produced by Shaanxi Buchang Gaoxin Pharmaceutical Co., LTD | Guangzhou Panyu Central Hospital; Guangzhou Panyu Central Hospital, Sponsor's funding | Prevention of thrombosis | | | | |
ChiCTR1800016430: Combined use of rivaroxaban and tranexamic acid for hemorrhage and thrombosis management in spine surgery |
|
|
| Recruiting | 4 | 2000 | | nothing ;Preoperative and intraoperative application of tranexamic acid ;Oral rivaroxaban 8 h after surgery, applied 35 days after surgery ;Preoperative and intraoperative application of tranexamic acid,oral rivaroxaban 8 h after surgery, applied 35 days after surgery | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Self-fund | Venous thromboembolism | | | | |
ChiCTR1800017265: Comparison of Effects and Complications of Different Anticoagulants Used after Arthroscopic Knee Surgery under the Concept of Enhanced Recovery |
|
|
| Not yet recruiting | 4 | 330 | | Rivaroxaban ;Enoxaparin | West Hospital, Sichuan University; West Hospital, Sichuan University, funding of sichuan university | Arthroscopic Knee Surgery | | | | |
ChiCTR1800018927: Combined application of rivaroxaban and tranexamic acid in the management of hemorrhage and thrombosis in traumatic surgery |
|
|
| Not yet recruiting | 4 | 1200 | | Physical prophylaxis Lower limb thrombosis ;1g of intravenous tranexamic acid before incision, maintained at 15mg/kg during operation ;1g of tranexamic acid before incision, maintained at 15mg/kg during operation, and rivaroxaban 8 hours after operation | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, Self-fund | Venous thromboembolism | | | | |
ChiCTR1800020289: A randomized controlled trial for Aspirin or Rivaroxaban for venous thromboembolism prophylaxis after total joint arthroplasty |
|
|
| Recruiting | 4 | 120 | | aspirin 100mg bid after operation ;Rivaroxaban 10mg qd after operation | Peking Union Medical College Hospital; Peking Union Medical College Hospital, Orthopaedic department, Peking Union Medical College Hospital | osteoarthritis | | | | |
2019-001336-62: Anticoagulation for Stroke Prevention In patients with Recent Episodes of perioperative Atrial Fibrillation after noncardiac surgery - The ASPIRE-AF trial |
|
|
| Not yet recruiting | 4 | 2800 | Europe | ELIQUIS, PRADAXA, RIVAROXABAN, EDOXABAN TOSILATO, [B01AF02], [B01AE07], [B01AF01], [edoxaban], Tablet, Capsule, hard, Apixaban 2,5 mg filmovertrukne tabletter, Edoxaban 30 mg filmovertrukne tabletter, Apixaban 5 mg filmovertrukne tabletter, Edoxaban 60 mg filmovertrukne tabletter, Rivaroxaban 15 mg filmovertrukne tabletter, Rivaroxaban 20 mg filmovertrukne tabletter, Dabigatran 110 mg, hårde kapsler | Hamilton Health Sciences Corporation, Population Health Research Institute, Canadian Institute of Health Research, Population Health Reserarch Institute. | Perioperative atrial fibrillation after noncardiac surgery, Fast, irregular heartbeat after noncardiac surgery, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2014-005162-29: Treatment of thrombosis in the abdominal veins Behandeling van trombose in de buikvenen |
|
|
| Not yet recruiting | 4 | 100 | Europe | rivaroxaban, Tablet, rivaroxaban 20 mg | University of Insubria, Amsterdam UMC, location AMC | Splanchnic vein thrombosis (SVT) is an unusual site manifestation of venous thromboembolism (VTE). It includes the Budd-Chiari syndrome (BCS), portal vein thrombosis (PVT), mesenteric vein thrombosis (MVT) and splenic vein thrombosis (spVT). PVT is the most frequent manifestation of SVT, followed by MVT. Splanchische veneuze trombose (SVT) is wat locatie betreft een ongewoonlijke manifestatie van veneuze trombo-embolie (VTE). Het bevat de Budd-Chiari syndrome, vena porta trombose, vena mesenterica trombose en vena lienalis/splenica trombose., The condition called splanchnic vein thrombosis (SVT) which causes decreased blood flow through one of your splanchnic veins (portal, mesenteric, or splenic vein). d. Bij splanchnische veneuze trombose wordt obstructie veroorzaakt in 1 van de aderen van het maagdarmstelsel, hierdoor kan het zuurstofarme bloed niet meer goed verder kan stromen., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR1800014852: Dual antiplatelet therapy contains rivaroxaban in advanced age patients with Atrial Fibrillation and Acute Coronary Syndromes without revascularization |
|
|
| Recruiting | 4 | 300 | | aspine plus clopidogrel ;aspine plus rivaroxaban ;clopidogrel plus rivaroxaban | Tianjin Union Medical Center; Tianjin Union Medical Center, self-raised | Acute coronary syndrome | | | | |
ChiCTR1900021589: Application of rivaroxaban in the study of factors related to coagulation function in perioperative period of hip and knee replacement |
|
|
| Not yet recruiting | 4 | 200 | | Rivaroxaban was used for anticoagulation during perioperative period ;Low molecular weight heparin (LMWH) was used in perioperative anticoagulation | Department of Orthopaedics, First Affiliated Hospital of Chongqing Medical University; First Affiliated Hospital of Chongqing Medical University, scientific research funds | Hip and knee replacement | | | | |
2018-003852-19: An Open Label, Non-Randomised, Phase IV Clinical Trial to Determine the Transfer of Apixaban and Rivaroxaban in Breast Milk Following Oral Administration |
|
|
| Not yet recruiting | 4 | 4 | Europe | Rivaroxaban, Apixaban, Film-coated tablet, Xarelto, Eliquis | King's College London, King's College Hospital NHS Foundation Trust, King's College London, Kings College London | healthy volunteers (Venous Thromboembolism), healthy volunteers (Blood clots during breast feeding), Diseases [C] - Blood and lymphatic diseases [C15] | | | | |
ChiCTR1900024985: Combined use of rivaroxaban and tranexamic acid for hemorrhage and thrombosis management in spine surgery |
|
|
| Not yet recruiting | 4 | 900 | | nothing ;The tranexamic acid 2g was intravenously instilled 30 minutes before the incision, and intraoperative local application of 1 g of tranexamic acid. ;Preoperative and intraoperative application of tranexamic acid,oral rivaroxaban 8 h after surgery, applied 35 days after surgery | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, self-funded | Venous thromboembolism | | | | |
2020-001053-44: Stabilization of atherosclerosis in carotid artery by Rivaroxaban as evaluated by 3D ultrasound with contrast |
|
|
| Not yet recruiting | 4 | 62 | Europe | Film-coated tablet, Xarelto® | Rigshospitalet, Department of Vascular Surgery, Bayer AG | Patients with - Stable peripheral artery diseaseand- Asymptomatic, atherosclerotic plaque/stenosis in the carotid artery; asymptomatic regarding cerebral ischaemia including stroke and transient ischaemic attack (TIA) or amaurosis fugax. Patienter med - Stabil perifer arteriel sygdomog - Asymptomatisk, aterosklerotisk plaque/stenose in carotis; asymptomatisk vedr. iskæmisk apopleksi inkluderende stroke og transient cerebral iskæmi (TCI) eller amaurosis fugax., Patients with: - Atherosclerosis in limb arteries and - Atherosclerosis in carotid artery with no symptoms of major or minor stroke or temporary vision loss. Patienter med:- Åreforkalkning i underekstremitets blodkarog- Åreforkalkning i halspulsåren uden symptomer på slagtilfælde eller forbigående synstab., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 4 | 382 | | rivaroxaban 10mg qd ;Placebo | The First Affiliated Hospital of Wenzhou Medical University; The First Affiliated Hospital of Wenzhou Medical University, No | Artery disease | | | | |
ChiCTR1800019890: Effect of gene polymorphism on the efficacy of direct oral anticoagulant therapy in patients with venous thromboembolism |
|
|
| Not yet recruiting | 4 | 200 | | Dabigatran ;Rivaroxaban | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, shanghai pulmonary hospital | venous thromboembolism | | | | |
2020-004913-11: Prescribing antithrombotic therapy in peripheral arterial disease, based on a DNA test. Beter voorschrijven van bloedverdunners bij perifeer arterieel vaatlijden op basis van DNA onderzoek. |
|
|
| Ongoing | 4 | 2244 | Europe | Clopidogrel, Rivaroxaban, Aspirin, Coated tablet, Clopidogrel, Rivaroxaban, Aspirin | Radboudumc, ZE&GG ZonMw | Symptomatic or stable pheripheral artery disease Lower extremity arterial disease., Lower extremity arterial disease. Vaatlijden van het been., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
NCT04059679: Synergistic Influence of Rivaroxaban on Inflammation and Coagulation Biomarkers in Patients With CAD and PAD on Aspirin Therapy |
|
|
| Recruiting | 4 | 30 | US | Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 81 mg | LifeBridge Health, Janssen Scientific Affairs, LLC | Coronary Artery Disease, Peripheral Artery Disease | 03/21 | 08/21 | | |
2020-005156-38: Alternative biological mechanisms underlying thrombus formation in acute myocardial infarction. Meccanismi biologici alternativi alla base della formazione del trombo nell'infarto miocardico acuto. |
|
|
| Not yet recruiting | 4 | 36 | Europe | RIVAROXABAN, TICAGRELOR, Clopidogrel, [B01AF01], [B01AC24], [B01AC/04], Tablet, BRILIQUE | AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Università del Piemonte Orientale | acute ST-segment elevation myocardial infarction (STEMI) with large coronary thrombus burden (LCTB). infarto acuto del miocardio con elevazione del tratto ST (STEMI) con elevato carico trombotico, acute heart attack caused by the occlusion of a coronary artery by a large amount of thrombus. infarto acuto del cuore causato dall'occlusione di una arteria coronaria da parte di una grande quantità di trombo., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 200 | RoW | Doxycycline Tablets, Doxycycline, Rivaroxaban 15Mg Tab, Hydroxychloroquine and Azithromycin | Yaounde Central Hospital | COVID-19 | 05/21 | 09/21 | | |
2016-002291-27: Randomized trial of aspirin versus rivaroxaban after replacement of the aortic valve with a biological valve prosthesis Randomiseret forsøg med Aspirin over for Rivaroxaban efter udskiftning af aortaklap med en biologisk proteseklap |
|
|
| Not yet recruiting | 4 | 1000 | Europe | Anticoagulant and preservative solution for blood, Xarelto, Aspirin | Aalborg University Hospital, Bayer Pharma AG | Aortic valve stenosis Aortaklapstenose, Stenosis of the aortic valve Forsnævring af aortaklappen, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Not yet recruiting | 4 | 200 | | Rivaroxaban + Ticagrelor | The First Affiliated Hospital of Dalian Medical University; The First Affiliated Hospital of Dalian Medical University, None | atrial fibrillation | | | | |
ChiCTR2000029081: Prospective Randomized Trial on Efficacy of Rivaroxaban and Wafarin on Preventing Vein Thromboembolism in Nephrotic Syndrome |
|
|
| Not yet recruiting | 4 | 144 | | 10mg/d Rivaroxaban on preventing vein thromboembolism ;Warfarin targeting INR 2-3 on preventing vein thromboembolism | Peking Union Medical College Hospital, Chinese Academy of Medical Science; Peking Union Medical College Hospital, Chinese Academy of Medical Science, Self-supporting | Nephrotic Syndrome | | | | |
2020-000353-26: Clinical Surveillance vs. Anticoagulation for Low-risk Patients with Isolated Subsegmental Pulmonary Embolism: A Multicenter Randomized Placebo-Controlled Non-Inferiority Trial |
|
|
| Not yet recruiting | 4 | 276 | Europe | Rivaroxaban, Rivaroxaban, Tablet, Xarelto (Rivaroxaban) | Bern University Hospital, Swiss National Science Foundation, Bayer AG | Isolated subsegmental pulmonary embolism, Small blood clots in the pulmonary arteries, so called isloated pulmonary embolism., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
2020-005110-17: Effects on human body of Rivaroxaban in patients with coronary artery disease and atrial fibrillation. Effetti sull'organismo umano di Rivaroxaban in pazienti con malattia coronarica e fibrillazione atriale |
|
|
| Not yet recruiting | 4 | 45 | Europe | Acido Acetilsalicilico, Xarelto 2,5 mg, Xarelto 20 mg, [B01AC06], [B01AF01], [038744189], Tablet | AZIENDA OSPEDALIERO UNIVERSITARIA MAGGIORE DELLA CARITà DI NOVARA, Università del Piemonte Orientale | stable CAD; history of atrial fibrillation coronaropatia stabile; storia di fibrillazione atriale., stable coronary artery disease; history of atrial fibrillation. malattia coronarica stabile; storia di fibrillazione atriale., Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2100049241: Effect and mechanism of Chemrin/CMKLR1 pathway in regulating the activities of coagulation factors II and X |
|
|
| Not yet recruiting | 4 | 80 | | Before start taking rivaroxaban. ;Before start taking rivaroxaban. ;Orally taken rivaroxaban 5mg/day for at a week. ; Orally taken rivaroxaban 5mg/day for at a week. ;Orally taken rivaroxaban 10mg/day for at a week. ;Orally taken rivaroxaban 10mg/day for at a week. ; Orally taken rivaroxaban 15mg/day for at a week. ;Orally taken rivaroxaban 15mg/day for at a week. | Guangzhou First People's Hospital; Guangzhou First People's Hospital, self-funded | Nonvalvular atrial fibrillation | | | | |
ChiCTR1800020395: Oral Direct Factor Xa Inhibitor (Rivaroxaban) in Patients With Post-thrombotic Syndrome (PTS) after Stent Implantation |
|
|
| Not yet recruiting | 4 | 200 | | Rivaroxaban ;warfarin | Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine; Shanghai Ninth People's Hospital, Shanghai JiaoTong University School of Medicine, No | Post-thrombotic Syndrome | | | | |
2019-003679-20: The effect of rivaroxaban with aspirin on improving the vascular function in patients with lower extremity arterial disease. |
|
|
| Not yet recruiting | 4 | 330 | Europe | Tablet, Xarelto, Aspirin | Radboudumc, Bayer B.V. | symptomatic or stable pheripheral artery disease, lower extremity arterial disease, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
TASK-POAF, NCT05300555: Cost-effectiveness Analysis Between Two Anticoagulation Strategies for Atrial Fibrillation in the Postoperative Period of Coronary Artery Bypass Graft Surgery |
|
|
| Recruiting | 4 | 50 | RoW | Rivaroxaban 20 MG Oral Tablet, Rivaroxaban, Warfarin | University of Sao Paulo General Hospital | Atrial Fibrillation New Onset | 01/22 | 11/22 | | |
2021-006189-19: The effect of rivaroxaban in addition to aspirin on the immune system in coronary artery disease |
|
|
| Ongoing | 4 | 20 | Europe | Tablet, Xarelto, Aspirin | Radboudumc, Not applicable | coronary artery disease, coronary artery disease, Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02] | | | | |
ChiCTR2100042086: A prospective, single arm, multicenter observational study on the compliance and effectiveness of NOAC (Rivaroxaban) in patients with high-risk atrial fibrillation |
|
|
| Recruiting | 4 | 200 | | N/A | West China Hospital, Sichuan University; West China Hospital, Sichuan University, no | atrial fibrillation | | | | |
ChiCTR2100044541: Effect of rivaroxaban on thromboprophylaxis in patients undergoing brain glioma surgery: a randomized, controlled, double-blind study |
|
|
| Recruiting | 4 | 150 | | Rivaroxaban P.O ;Oral placebo | The First Affiliated Hospital of Zhengzhou University; The First Affiliated Hospital of Zhengzhou University, Hospital Youth Fund | brain glioma | | | | |
ChiCTR2000031133: The Efficacy and Safety of Rivaroxaban for Thromboprophylaxis in High-risk Cancer Patients With PICC: a Prospective Randomized Controlled Trial |
|
|
| Recruiting | 4 | 204 | | oral Rivaroxaban 10mg per day for 90 days ;mechanical prophylaxis | LiuZhou People's Hospital; Liuzhou People's Hospital, None | Catheter-related thrombosis | | | | |
| Active, not recruiting | 4 | 20 | Europe | Rivaroxaban 2.5 Mg Oral Tablet | Radboud University Medical Center | Coronary Artery Disease | 04/22 | 07/22 | | |
| Completed | 4 | 234 | RoW | Rivaroxaban and aspirin 80, Aspirin 80 | Shiraz University of Medical Sciences | Post Coronary Bypass Surgery Patients | 05/22 | 07/22 | | |
ChiCTR2100046685: Population pharmacokinetic/pharmacodynamic analysis of rivaroxaban in non-valvular atrial fibrillation patients |
|
|
| Recruiting | 4 | 100 | | Nil ;Nil | Huashan Hospital, Fudan University; Huashan Hospital, Fudan University, New Star of Medical Garden——Shanghai Excellent Clinical Pharmacist | non-valvular atrial fibrillation | | | | |
2021-005022-18: Preventing formation of blood clots due to atrial fibrillation, a cardiac arrhythmia that first occurred after coronary bypass surgery, with the help of anticoagulant medications. Vorbeugung der Bildung von Blutgerinnseln durch Vorhofflimmern, einer Herzrhythmusstörungen, die nach einer koronaren Bypass-Operation erstmalig aufgetreten ist, mit Hilfe von gerinnungshemmenden Medikatmenten. |
|
|
| Not yet recruiting | 4 | 3200 | Europe | Marcumar, Dabigatran, Xarelto, Apixaban, Edoxaban, Aspirin, Brilique, Clopidogrel, B01AC04, Tablet, Capsule, hard, Marcumar, Pradaxa, Xarelto, Eliquis, Lixiana, Aspirin, Brilique, Clopidogrel | Icahn School of Medicine at Mount Sinai, NIH/NHLBI | New-Onset Post-Operative Atrial Fibrillation afterCABG Neu auftretendes postoperatives Vorhofflimmernnach CABG, New-Onset Post-Operative Atrial Fibrillation aftercoronary artery bypass graft (bridging of constrictions in coronary vessels) Neu aufgetretenes Vorhofflimmern nach einerkoronaren Bypassoperation (Überbrückung von Engstellen in Herzkranzgefäßen), Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2100042259: Effectiveness and safety of sulfonate in the prevention of venous thromboembolism after hip fracture |
|
|
| Recruiting | 4 | 90 | | Sulfonda liver decanodium 2.5mg, subcutaneous injection. ;Enoxaparin sodium 4000IU (Sanofi) subcutaneous injection ;Oral rivaroxaban 10mg (Bayer) | Affiliated Hospital of North Sichuan Medical College; Affiliated Hospital of North Sichuan Medical College, Sichuan Medical Association | Hip fracture | | | | |
| Completed | 4 | 48 | Europe | Aspirin 75mg, Aspirin 20mg, Rivaroxaban 2.5 mg | Sheffield Teaching Hospitals NHS Foundation Trust | Coronary Syndrome | 08/23 | 12/23 | | |
NCT04805710: Rivaroxaban or Aspirin in Patients With CHD & GD Undergoing PCI |
|
|
| Not yet recruiting | 4 | 1020 | NA | clopidogrel combined with rivaroxaban arm, clopidogrel combined with rivaroxaban | Shenyang Northern Hospital | Rivaroxaban | 09/22 | 12/23 | | |
ChiCTR2100049891: Sequential use of different anticoagulant drugs for prevention of venous thromboembolism in hospitalized patients with traumatic fractures: a multi-center, prospective and practical clinical study |
|
|
| Not yet recruiting | 4 | 7414 | | Fondaparinux (during hospitalization) + Rivaroxaban/low molecular weight heparin/Fondaparinux (after discharge); low molecular weight heparin (during hospitalization) + rivaroxaban/low molecular weight heparin/fondaparinux (after discharge) | Qilu Hospital of Shandong University; Qilu Hospital of Shandong University, China Red Cross Foundation | Prevention of venous thromboembolic events | | | | |
NCT02974920: Rivaroxaban or Aspirin for Biological Aortic Prosthesis |
|
|
| Recruiting | 4 | 1000 | Europe | Rivaroxaban 10 MG, Aspirin | Christian Torp-Pedersen, Aalborg University Hospital, Aarhus University Hospital, Odense University Hospital, Rigshospitalet, Denmark | Aortic Stenosis, Aortic Regurgitation, Thrombosis | 11/22 | 11/22 | | |
ChiCTR2100049083: Prospective study of rivaroxaban in the reversal of compensatory cirrhosis |
|
|
| Recruiting | 4 | 120 | | rivaroxaban 10mg, orally once a day for 96 weeks ;No any anti liver fibrosis medicine include TCM | Beijing Youan Hospital, Capital Medical University; Beijing Youan Hospital ，Capital Medical University, Self-financing | Compensatory liver cirrhosis | | | | |
2017-000236-34: Early versus Late initiation of direct oral Anticoagulants in post-ischaemic stroke patients with atrial fibrillatioN (ELAN): an international, multicentre, randomised-controlled, two-arm, assessor-blinded trial |
|
|
| Not yet recruiting | 4 | 2000 | Europe | ELIQUIS 5 MG COMPRESSE RIVESTITE CON FILM, PRADAXA 150 MG CAPSULE RIGIDE, XARELTO 20 MG COMPRESSE RIVESTITE CON FILM, LIXIANA 60 MG COMPRESSE RIVESTITE CON FILM, [041225145], [038451100], [038744189], [044315188], Film-coated tablet, Capsule, hard, Xarelto 20 mg film-coated tablets, Pradaxa 150 mg hard capsules, Lixiana 60 mg film-coated tablets, Eliquis 5 mg film-coated tablets | Inselspital (University Hospital) Bern, Insel Gruppe AG, Bern University Hospital, Department of Neurology, Swiss National Science Foundation, Swiss Heart Foundation, Stroke Association | Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke, Recurrent strokes in patients with atrial fibrillation who suffered an ischaemic stroke, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2000033145: Study on the correlation between protein C system-related protein expression level and the anticoagulant effect of rivaroxaban and dabigatran |
|
|
| Not yet recruiting | 4 | 100 | | 无 ;无 | The Fifth People's Hospital of Shanghai; The Fifth People's Hospital of Shanghai, Scientific Research Project funded by The Fifth People's Hospital of Shanghai | Atrial fibrillation | | | | |
ChiCTR2100046333: A multi-center, randomized controlled clinical evaluation study of Naoxintong Capsules for improving the quality of life of patients with non-valvular atrial fibrillation after PCI |
|
|
| Recruiting | 4 | 240 | | Dual therapy of rivaroxaban (15 mg, once/d) + clopidogrel (75 mg, once/d) to 6 months after PCI ;The antithrombotic treatment plan of the control group + Naoxintong capsule, orally. 4 capsules at a time, 3 times a day. | Fujian Provincial Hospital; Shanxi Buchang Pharmaceutical Co., Ltd., Corporate funding | Patients with nonvalvular atrial fibrillation after PCI | | | | |
ChiCTR1900026249: Clinical study for a new oral anticoagulant to prevent left ventricular thrombus in patients with acute anterior wall myocardial infarction |
|
|
| Recruiting | 4 | 280 | | Rivaroxaban + DAPT ;Basic treatment | China-Japan Union Hospital of Jilin University; China-Japan Union Hospital of Jilin University, Project of jilin Development and Reform Commission | coronary artery disease | | | | |
REVISE-AF, NCT06187311: Clinical Trial to Evaluate Efficacy and Safety of Rivaroxaban 15mg and 20mg in Patients With Non-valvular Atrial Fibrillation |
|
|
| Recruiting | 4 | 940 | RoW | Rivaroxaban 20 MG, Rivaroxaban 15 MG | Korea University Anam Hospital | Atrial Fibrillation, Anticoagulant Adverse Reaction | 06/26 | 06/27 | | |
ChiCTR2100041689: Study on the correlation between the risk of thrombosis and bleeding after hip and knee replacement and the effect of anticoagulation |
|
|
| Recruiting | 4 | 600 | | aspirin ;Enoxaparin ;Rivaroxaban | The Second Affiliated Hospital of Kunming Medical University; The Second Affiliated Hospital of Kunming Medical University, The Second Affiliated Hospital of Kunming Medical University | Hip and knee replacement, deep vein thrombosis | | | | |
| Recruiting | 4 | 48 | Europe | Rivaroxaban 20 MG, Warfarin | University Hospital, Angers, Bayer | Nonvalvular Atrial Fibrillation | 02/23 | 02/23 | | |
NCT04853719: Rivaroxaban 2.5 mg BID and Aspirin for Intermittent Claudication in PAD Patients |
|
|
| Completed | 4 | 88 | RoW | Rivaroxaban 2.5 Mg Oral Tablet, Aspirin 100 Mg oral Tablet | Science Valley Research Institute, Bayer | Peripheral Artery Disease, Intermittent Claudication | 02/23 | 02/23 | | |
ChiCTR2100051990: Efficacy and Safety of Rivaroxaban Versus Aspirin in Patients with Small Abdominal Aortic Aneurysm and Elevated High sensitivity C Protein: A Randomized Controlled Trail |
|
|
| Recruiting | 4 | 60 | | Rivaroxaban+pitavastatin ;Aspirin+pitavastatin | The PLA Northern Theater Command General Hospital; The PLA Northern Theater Command General Hospital, None | Abdominal aortic aneurysm | | | | |
ChiCTR2100048098: Rivaroxaban versus warfarin in the treatment of left ventricular thrombosis: a randomized controlled, non-inferior clinical study |
|
|
| Not yet recruiting | 4 | 216 | | Rivaroxaban 15 mg ;Starting warfarin 2.5 mg qd, adjusting warfarin dosage to stabilize PT-INR at 2.0-3.0 | Sun Yat-sen Memorial Hospital of Sun Yat-sen University; Sun Yat-sen Memorial Hospital of Sun Yat-sen University, Jointly funded project of Guangzhou Science and technology plan | Left ventricular thrombosis | | | | |
ACCP, NCT05573958: To Assess the Efficacy and Safety of Dual Anticoagulants i.e. Rivaroxaban Plus Aspirin and Clopidogrel Plus Aspirin in Patients Suffering From an Acute Coronary Syndrome |
|
|
| Not yet recruiting | 4 | 90 | NA | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Clopidogrel tablet, Plavix, Aspirin tablet, Acetylsalicylic acid | Sarmad Zahoor, University of Managemant and Technology, Pakistan, Mayo Hospital Lahore | Acute Coronary Syndrome | 03/23 | 07/23 | | |
ChiCTR2200062928: Effects of oral dronedarone hydrochloride tablets on NOACs concentrations in patients with paroxysmal or persistent atrial fibrillation: a randomized, controlled, single-center clinical study |
|
|
| Not yet recruiting | 4 | 75 | | Amiodarone 200mg qd combined with dabigatran 110mg bid for 1 month ;Dronedarone 400mg bid plus dabigatran 110mg bid for 1 month ;Dabigatran 150mg bid for 1 month ;Amiodarone 200mg qd combined with rivaroxaban 15mg qd for 1 month ;Dronedarone 400mg bid combined with rivaroxaban 15mg qd for 1 month ;Rivaroxaban 20mg qd for 1 month | The First Hospital of China Medical University; The First Hospital of China Medical University, The CSPC Ouyi Pharmaceutical Co., Ltd | Atrial fibrillation | | | | |
| Not yet recruiting | 4 | 78 | Europe | Rivaroxaban, cardioaspirin 100ml, [bay59-7939], [24840074], Tablet, Gastro-resistant tablet, XARELTO - 2,5 MG - COMPRESSE RIVESTITE CON FILM - USO ORALE - BLISTER (PP/ALU) - 56 COMPRESSE, CARDIOASPIRIN - 100 MG COMPRESSE GASTRORESISTENTI30 COMPRESSE | FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE, Bayer S.p.A. | type 2 diabetic patients with stable peripheral or carotid artery disease diabete mellito di tipo 2 e vasculopatia arteriosa periferica o carotidea stabile, na na, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
| Recruiting | 4 | 320 | RoW | Rivaroxaban, Warfarin | National Institute of Cardiovascular Diseases, Pakistan | Acute Coronary Syndrome, Left Ventricular Thrombus | 12/23 | 01/24 | | |
Ésquilo, NCT05303818: Chemoprophylaxis With Rivaroxaban for Lower Limb Deep Vein Thrombosis in Colorectal Cancer |
|
|
| Not yet recruiting | 4 | 68 | RoW | Rivaroxaban 10 MG | Hospital do Servidor Publico Estadual | Deep Venous Thrombosis, Colonic Cancer | 06/23 | 06/24 | | |
2019-000794-23: AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé ensimple aveugle comparant les effets neurocognitifs du rivaroxaban parrapport à un antagoniste de la vitamine K AntiCoagulants et COGnition (essai ACCOG) : Essai contrôlé randomisé ensimple aveugle comparant les effets neurocognitifs du rivaroxaban parrapport à un antagoniste de la vitamine K |
|
|
| Not yet recruiting | 4 | 48 | Europe | Xarelto® 20mg (Rivaroxaban), COUMADINE® (warfarine), Coated tablet, Tablet, XARELTO® 20 mg, COUMADINE® | CHU ANGERS, CHU ANGERS, BAYER | fibrillation atriale non valvulaire fibrillation atriale non valvulaire, fibrillation atriale non valvulaire fibrillation atriale non valvulaire, Diseases [C] - Cardiovascular Diseases [C14] | | | | |
ChiCTR2200063471: Effect of Low-dose vs Standard-dose Rivaroxaban Prophylaxis on Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: a Randomized Clinical Trial |
|
|
| Not yet recruiting | 4 | 108 | | Rivaroxaban (5 mg po qd) ;Rivaroxaban (10 mg po qd) | The Second Affiliated Hospital of Chongqing Medical University; The Second Affiliated Hospital of Chongqing Medical University, Self-funded | Osteoarthritis | | | | |
ChiCTR2100050255: Clinical study of dual-channel antithrombotic therapy for the prevention of left ventricular thrombosis in acute anterior wall myocardial infarction |
|
|
| Recruiting | 4 | 300 | | Ticagrelor and rivaroxaban ;Traditional dual antiplatelet therapy | China-japan Union Hospital of Jilin University; China-japan Union Hospital of Jilin University, Project of jilin Development and Reform Commission | coronary artery disease | | | | |
| Recruiting | 4 | 1512 | Europe | CE-mark approved LAA closure devices, Acetylsalicylic acid, ASS, Clopidogrel, Dabigatran, Pradaxa®, Rivaroxaban, Xarelto®, Apixaban, Eliquis®, Edoxaban, LIXIANA®, Phenprocoumon, Marcumar®, Warfarin, Coumadin® | Charite University, Berlin, Germany, Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK), Atrial Fibrillation Network, Stiftung Institut fuer Herzinfarktforschung | Atrial Fibrillation | 09/23 | 03/25 | | |
ERSAF, NCT03749057: Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation |
|
|
| Recruiting | 4 | 400 | RoW | Rivaroxaban | General Hospital of Shenyang Military Region | Cerebral Infarction, TIA | 06/24 | 06/24 | | |
DEFINE CCS, NCT05116995: Differential EFfects of Dual antIplatelet and Dual aNtithrombotic thErapy on Hemostasis in Chronic Coronary Syndrome Patients |
|
|
| Recruiting | 4 | 30 | Canada | Rivaroxaban, xarelto, Ticagrelor, brilinta | Nova Scotia Health Authority | Thrombosis, Myocardial Infarction | 11/23 | 11/23 | | |
| Completed | 4 | 21 | Europe | Rivaroxaban 20mg, Xarelto, Sotorasib 960mg, Lumykras | Radboud University Medical Center, Amgen | Drug Drug Interaction Study | 03/24 | 03/24 | | |
ANDES, NCT03568890: Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure |
|
|
| Recruiting | 4 | 510 | Canada | Rivaroxaban, dabigatran, apixaban, or edoxaban, Clopidogrel -75 mg/day, Low dose aspirin -80 to 125 mg/day- | Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec | Left Atrial Appendage Closure, Thrombosis, Stroke, TIA, Bleeding | 12/25 | 09/26 | | |
ChiCTR2000036449: Study for comparison of Efficacy and safetystudy between rivaroxaban and warfarin in prophylactic anticoagulant therapy for nephrotic syndrome |
|
|
| Not yet recruiting | 4 | 600 | | Rivaroxaban ;warfarin | Shanghai First People's Hospital; Shanghai First People's Hospital, Shanghai Board of Health | nephrotic syndrome | | | | |
ChiCTR2100044319: The efficacy and safety of clopidogrel combined with rivaroxaban and aspirin in patients with coronary heart disease and gastrointestinal diseases undergoing PCI: a randomized controlled study |
|
|
| Recruiting | 4 | 1020 | | clopidogrel combined with rivaroxaban ;clopidogrel combined with aspirin | General Hospital of Northern Theater Command; General Hospital of Northern Theater Command, Natural Science Foundation of Liaoning Province | coronary heart disease and gastrointestinal diseases | | | | |
ESRETP, ChiCTR2000036790: The efficacy and safety of Rivaroxaban and Enoxaparin for thromboprophylaxis after pulmonary surgery for cancer: a single, randomized, single-blind, parallel control clinical study. |
|
|
| Not yet recruiting | 4 | 740 | | oral take rivaroxaban ;Hypodermic injection of Enoxaparin | Shanghai Pulmonary Hospital; Shanghai Pulmonary Hospital, Shenkang Hospital Development Center of Shanghai | Venous Thromboembolism | | | | |
RENOVATE, NCT04258488: Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement |
|
|
| Recruiting | 4 | 1300 | RoW | Rivaroxaban Oral Tablet, Vitamin K antagonist(warfarin) | Jung-min Ahn | AORTIC VALVE DISEASES, Thromboembolism | 12/24 | 06/25 | | |
ChiCTR2000040540: Efficacy prediction of rivaroxaban combined with targeted therapy and immunotherapy for advanced hepatocellular carcinoma |
|
|
| Not yet recruiting | 4 | 100 | | 1 ;2 | Lanzhou University Second Hospital; Lanzhou University Second Hospital, Self-raising | Advanced hepatocellular carcinoma | | | | |
SAFE-SSPE, NCT04263038: Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism |
|
|
| Recruiting | 4 | 276 | Europe, Canada | Rivaroxaban, Placebo | Drahomir Aujesky, University of Bern, Schweizerischer Nationalfonds, Leiden University Medical Center, The Ottawa Hospital, Bayer | Pulmonary Embolism, Embolism, Embolism and Thrombosis, Lung Diseases, Cardiovascular Diseases, Respiratory Tract Diseases, Venous Thromboembolism, Anticoagulant-induced Bleeding, Bleeding | 05/26 | 05/26 | | |
| Recruiting | 4 | 196 | RoW | Rivaroxaban, Warfarin | Shahid Gangalal National Heart Centre | Left Ventricular Thrombus, Myocardial Infarction | 03/25 | 04/25 | | |
| Terminated | 4 | 9 | Canada | tinzaparin, Rivaroxaban | Sunnybrook Health Sciences Centre, LEO Pharma, Sunnybrook Research Institute | Deep Vein Thrombosis, Post Thrombotic Syndrome | 01/24 | 01/24 | | |
COBRRA, NCT03266783: Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism |
|
|
| Recruiting | 4 | 2760 | Europe, Canada, RoW | Apixaban, Eliquis, Rivaroxaban, Xarelto | Ottawa Hospital Research Institute, Canadian Institutes of Health Research (CIHR), Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network | Venous Thromboembolism | 08/24 | 12/24 | | |
COMPETE, NCT05546320: Comparison of the Effect of Medication Therapy in Alleviating Migraine With Patent Foramen Ovale |
|
|
| Recruiting | 4 | 1000 | RoW | Aspirin 100mg, Metoprolol 25 Mg Oral Tablet, Clopidogrel 75mg, Rivaroxaban 20mg | Chinese Academy of Medical Sciences, Fuwai Hospital | Patent Foramen Ovale, Migraine | 06/24 | 06/25 | | |
WRAP, NCT05973188: Safety and Efficacy of Rivaroxaban and Apixaban in Comparison to Warfarin in Left Ventricular Clot- Clinical Trial |
|
|
| Recruiting | 4 | 141 | RoW | Warfarin, Warfarin oral tablet, Rivaroxaban 20 MG Oral Tablet, Xcept, Apixaban 5mg or 2.5mg oral tablet, Apixaget | Peshawar Institute of Cardiology, Getz Pharma | Left Ventricular Thrombus | 06/24 | 06/24 | | |
ChiCTR2300072495: A metabolomics-based study on the intervention effect and mechanism of Qitao Huayu formula for the treatment of hypercoagulable state after TKA |
|
|
| Not yet recruiting | 4 | 110 | | Qitao Huayu formula and physical prevention ;Rivaroxaban and physical prevention | Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine; Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine, Construction of a multidisciplinary service model for rapid rehabilitation of Chinese and Western medicine in artificial knee joint replacement | total knee arthroplasty | | | | |
ARCHIMEDES, NCT06396858: Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke |
|
|
| Not yet recruiting | 4 | 4500 | NA | Rivaroxaban 2.5 Mg Oral Tablet, Xarelto, Colchicine 0.5 MG, Colchis, Placebo Rivaroxaban, Placebo Colchicine | Brazilian Clinical Research Institute, Alliança Diagnostic | Ischemic Stroke | 06/26 | 12/26 | | |
